Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm Phase I/II Study Evaluating the Safety and Clinical Efficacy Of the 2-nd Generation CD19 Autologous CAR T Cells on the CliniMACS Prodigy Automated Manufacturing Platform in Treatment of Paediatric And Young Adult Patients With Relapsed/Refractory B-lineage Acute Lymphoblastic Leukemia

NCT03467256 is registered in ClinicalTrials.gov with Federal Research Institute of Pediatric Hematology, Oncology and Immunology as lead sponsor.

NCT NCT03467256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03467256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm Phase I/II Study Evaluating the Safety and Clinical Efficacy Of the 2-nd Generation CD19 Autologous CAR T Cells on the CliniMACS Prodigy Automated Manufacturing Platform in Treatment of Paediatric And Young Adult Patients With Relapsed/Refractory B-lineage Acute Lymphoblastic Leukemia
Lead sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 14, 2018
Completion date
October 15, 2025
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, pediatric, b-cell acute lymphoblastic leukemia